

HHS Public Access

Author manuscript *N Engl J Med.* Author manuscript; available in PMC 2024 May 07.

Published in final edited form as:

N Engl J Med. 2023 August 10; 389(6): 491–503. doi:10.1056/NEJMoa2302983.

Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer

Heather Wakelee, MD¹, Moishe Liberman, MD, PhD², Terufumi Kato, MD³, Masahiro Tsuboi, MD, PhD⁴, Se-Hoon Lee, MD, PhD⁵, Shugeng Gao, MD, PhD⁶, Ke-Neng Chen, MD, PhD⁷, Christophe Dooms, MD, PhD⁸, Margarita Majem, MD, PhD⁹, Ekkehard Eigendorff, MD¹⁰, Gastón L Martinengo, MD¹¹, Olivier Bylicki, MD¹², Delvys Rodríguez-Abreu, MD, PhD¹³, Jamie Chaft, MD¹⁴, Silvia Novello, MD, PhD¹⁵, Jing Yang, PhD¹⁶, Steven M Keller, MD¹⁶, Ayman Samkari, MD¹⁶, Jonathan D Spicer, MD, PhD¹⁷, KEYNOTE-671 Investigators^{*} ¹Stanford University School of Medicine/Stanford Cancer Institute. Stanford, CA, USA

²Centre Hospitalier de Universite to Montréal (CHUM), Montréal, QC, Canada

³Kanagawa Cancer Center, Yokohama, Japan

⁴National Cancer Center Hospital East, Kashiwa, Japan

⁵Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea

⁶National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

⁷Beijing Cancer Hospital, Peking University, Beijing, China

⁸University Hospitals Leuven, Leuven, Belgium

⁹Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

¹⁰Zentralklinik Bad Berka, Bad Berka, Germany

¹¹Sanatorio Parque, Córdoba, Argentina

¹²HIA Sainte-Anne, Toulon, France

¹³Hospital Universitario Insular de Gran Canaria, Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain

¹⁴Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, USA

¹⁵Department of Oncology, University of Turin, A.O.U. San Luigi Gonzaga di Orbassano, Turin, Italy

¹⁶Merck & Co. Inc., Rahway, NJ, USA

Addresses for Correspondence Heather Wakelee, MD, FASCO, Professor of Medicine and Chief of the Division of Oncology, Stanford University School of Medicine; Deputy Director, Stanford Cancer Institute, 269 Campus Drive, CCSR 1115, MC: 5151, Stanford, CA 94305, hwakelee@stanford.edu.

^{*}A complete list of investigators who participated in the KEYNOTE-671 study is provided in the Supplementary Appendix, available at NEJM.org.

¹⁷McGill University Health Centre, Montréal, QC, Canada

Abstract

Background: We conducted a randomized, double-blind, phase 3 study to evaluate perioperative pembrolizumab in early-stage NSCLC.

Methods: Participants with resectable stage II, IIIA, or IIIB (N2) NSCLC were randomized (1:1) to neoadjuvant pembrolizumab 200mg or placebo once every 3 weeks plus cisplatin-based chemotherapy for 4 cycles followed by surgery and adjuvant pembrolizumab 200mg or placebo once every 3 weeks for 13 cycles. Dual primary endpoints were event-free survival and overall survival. Secondary endpoints included major pathological response, pathological complete response, and safety.

Results: 797 participants were randomized to the pembrolizumab (n=397) or placebo (n=400) group. At the prespecified first interim analysis, median follow-up was 25.2 months. 24-month event-free survival rates were 62.4% in the pembrolizumab group versus 40.6% in the placebo group (HR, 0.58; 95% CI, 0.46–0.72; P<0.00001). 24-month overall survival estimates were 80.9% versus 77.6% (P=0.02124). Major pathologic response rates were 30.2% versus 11.0% (difference, 19.2; 95% CI, 13.9–24.7; P<0.00001). Pathologic complete response rates were 18.1% versus 4.0% (difference, 14.2; 95% CI, 10.1–18.7; P<0.00001). Across all treatment phases, 44.9% of participants in the pembrolizumab group and 37.3% in the placebo group had grade 3 treatment-related adverse events, including 1.0% and 0.8% who had grade 5 events.

Conclusions: Neoadjuvant pembrolizumab plus chemotherapy followed by resection and adjuvant pembrolizumab significantly improved event-free survival, major pathologic response, and pathologic complete response compared with neoadjuvant chemotherapy alone in resectable, early-stage NSCLC. Overall survival was not significantly different at this analysis. (Funded by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA; ClinicalTrials.gov number, NCT03425643.)

Introduction

Programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) immune checkpoint inhibitor-based regimens are standard treatments for advanced or metastatic non-small cell lung cancer (NSCLC) without targetable molecular drivers.^{1–5} The benefit of these drugs in earlier disease stages was first seen in the PACIFIC trial, in which the PD-L1 inhibitor durvalumab improved progression-free survival and overall survival when given after concurrent chemoradiotherapy for unresectable stage III NSCLC.^{6,7} Results of several phase 2 studies suggested a benefit for PD-1/PD-L1 inhibitors given as monotherapy or in combination with chemotherapy in the neoadjuvant NSCLC setting.^{8–10} This benefit was confirmed in the phase 3 CheckMate 816 trial in which neoadjuvant nivolumab plus chemotherapy improved event-free survival compared with neoadjuvant chemotherapy alone (hazard ratio, 0.63 [97.38% CI, 0.43–0.91], P=0.005).¹¹

The IMpower010 study provided the first evidence of benefit for adjuvant checkpoint inhibition, showing that the PD-L1 inhibitor atezolizumab improved disease-free survival versus placebo when given after complete resection and adjuvant chemotherapy in patients

with PD-L1-expressing, stage II-IIIA NSCLC (hazard ratio, 0.66 [95% CI, 0.50–0.88], P=0.0039).¹² The PEARLS/KEYNOTE-091 study similarly demonstrated a disease-free survival benefit for adjuvant therapy with the PD-1 inhibitor pembrolizumab given after complete resection and, when recommended by guidelines, adjuvant chemotherapy in a PD-L1-unselected population of patients with stage IB-IIIA NSCLC (hazard ratio, 0.76 [95% CI, 0.63–0.91], P=0.0014).¹³

Neoadjuvant nivolumab plus chemotherapy and single-agent adjuvant atezolizumab and pembrolizumab are all approved by the US FDA and have various global indications; however, either approach alone leaves many patients at risk of relapse and eventual death from NSCLC. In the placebo-controlled, phase 3 KEYNOTE-671 trial, we assessed whether a perioperative approach of combined neoadjuvant pembrolizumab plus cisplatin-based chemotherapy followed by surgical resection and adjuvant pembrolizumab improves efficacy compared with neoadjuvant cisplatin-based chemotherapy and resection alone in resectable stage II-III NSCLC. We report efficacy and safety data from the prespecified first interim analysis.

Methods

Participants

Participants were eligible for enrollment if they provided written, informed consent; were aged 18 years; had previously untreated, pathologically confirmed, stage II, IIIA, or IIIB (N2) NSCLC assessed per the American Joint Committee on Cancer staging system (8th edition¹⁴; details available in the Supplementary Methods and Table S1) considered resectable after surgical consultation and investigator assessment; had Eastern Cooperative Oncology Group performance-status score of 0 or 1 (on a 5-point scale, with 0 indicating no symptoms and higher scores indicating increasing disability¹⁵) within 10 days of randomization; and were able to provide a tumor sample for PD-L1 assessment at a central laboratory. Full eligibility criteria are available in Section 6 of the protocol, available with the full text of this article at NEJM.org.

Trial Design and Treatments

In this double-blind, placebo-controlled, phase 3 study, randomization was performed centrally using an interactive response system. Participants were stratified by stage (II vs III), PD-L1 tumor proportion score (<50% vs 50% based on PD-L1 IHC 22C3 pharmDx [Agilent Technologies]), histology (squamous vs nonsquamous), and geographic region (east Asia vs not east Asia) and randomized (1:1) to receive pembrolizumab or placebo. Neoadjuvant therapy comprised four cycles of pembrolizumab (200 mg) or placebo given intravenously once every 3 weeks plus cisplatin and gemcitabine (squamous histology) or cisplatin and pemetrexed (nonsquamous histology); 4 cycles of neoadjuvant therapy at the time of study design in 2017. Surgery was to be performed per local standards no later than 20 weeks after the first neoadjuvant therapy dose; radiotherapy was administered in select circumstances. Adjuvant therapy was to be initiated no sooner than 4 weeks and no later than 12 weeks after surgery and comprised pembrolizumab (200 mg) or placebo

given intravenously once every 3 weeks for up to 13 additional cycles. Treatment was continued until disease progression or recurrence, intolerable toxicity, investigator decision, withdrawal of consent, or other reasons (summarized in the Supplementary Appendix). Additional treatment information, including chemotherapy regimen and lymphadenectomy details and circumstances in which radiotherapy was to be administered, is available in the Supplementary Appendix.

Page 4

Assessments and Endpoints

Pathological response following neoadjuvant therapy was assessed by examination of hematoxylin-and-eosin-stained slides of resected lung tissue and lymph nodes. Definitions of R0, R1, and R2 resection are outlined in the Supplementary Appendix. Computed tomography (strongly preferred) or magnetic resonance imaging of the chest and abdomen was performed during screening, throughout all treatment phases, and during follow-up according to the schedule outlined in the Supplementary Appendix. While imaging was performed after neoadjuvant therapy but before surgery, tumors were not formally restaged before surgery. Participants were contacted for survival every 12 weeks. Adverse events and laboratory abnormalities were assessed regularly throughout all treatment phases and for 30 days after discontinuation (up to 90 days for serious events in the absence of new anticancer therapy) and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.03. Potentially immune-mediated adverse events and infusion reactions were based on a list of preferred terms prepared by the sponsor and considered regardless of attribution to treatment by the investigator. *EGFR* mutation and *ALK* translocation status were tested locally per investigator discretion.

Dual primary endpoints were event-free survival (time from randomization to first occurrence of local progression precluding planned surgery, unresectable tumor, progression or recurrence per RECIST 1.1 by investigator assessment, or death from any cause) and overall survival (time from randomization to death from any cause). Key secondary endpoints included major pathological response (10% viable tumor cells in resected primary tumor and lymph nodes) and pathological complete response (absence of residual invasive cancer in resected primary tumor and lymph nodes [ypT0/Tis ypN0]) assessed by blinded, central pathologist examination and safety.

Trial Oversight

A panel of academic advisors and sponsor employees designed the study. An external, independent data and safety monitoring committee oversees the trial, assessing safety regularly and efficacy at prespecified interim analyses. The protocol and all amendments were approved by the appropriate ethics body for each participating center. All authors vouch for data accuracy and completeness and study conduct in accordance with the protocol, its amendments, and Good Clinical Practice guidelines. All authors attest they participated in writing or reviewing and editing the manuscript. A medical writer employed by the sponsor assisted with manuscript preparation.

Statistical Analysis

Efficacy was assessed in the intention-to-treat population (all randomized participants).

Safety was assessed in the as-treated population (all randomized participants who received 1 dose of study treatment). Event-free survival and overall survival were estimated using the Kaplan-Meier method. The magnitude of the treatment differences (i.e., hazard ratios and associated 95% confidence intervals [CIs]) was calculated using a stratified Cox regression model with treatment as a covariate and Efron's method of handling ties; between-group differences were assessed using the stratified log-rank test. If the proportional hazards assumption was not valid, the restricted mean survival time method¹⁶ was performed as a sensitivity analysis. Between-group comparisons of the percentage of participants with major pathological response and the percentage with pathological complete response were performed using the stratified Miettinen and Nurminen method with strata weighting by sample size. The randomization stratification factors were applied to all stratified analyses.

The statistical analysis plan is available in protocol Section 10. The graphical method of Maurer and Bretz¹⁷ was used to strictly control the family-wise type I error rate at one-sided α =0.025 across the event-free survival, overall survival, major pathological response, and pathological complete response hypotheses among the interim and final analyses (Fig. S1). The Lan-DeMets O'Brien-Fleming spending function will be used to control type I error for event-free survival and overall survival in the interim and final analyses. Power statements for each hypothesis are in the Supplementary Appendix. The study is considered positive if at least one of the primary endpoints is significantly improved in the pembrolizumab group.

The data reported herein are from the first interim analysis (data cutoff, July 29, 2022), which was to be performed \sim 5 months after the last participant was randomized and after \sim 326 event-free survival events occurred. On the basis of the observed number of events, the multiplicity-adjusted one-sided alpha levels at this analysis were 0.00462 for event-free survival, 0.0001 for major pathological response, and 0.0001 for pathological complete response.

Results

Participants and Treatment

Between April 2018 and December 2021, 1364 participants were screened and 797 were randomized to treatment with neoadjuvant pembrolizumab plus chemotherapy followed by surgery and adjuvant pembrolizumab (pembrolizumab group; n = 397) or with neoadjuvant placebo plus chemotherapy followed by surgery and adjuvant placebo (placebo group; n = 400) (Fig. S2). Baseline demographics and disease characteristics were balanced between groups (Table 1) and generally representative of the broader lung cancer population (Table S2). Although Black or African American participants were underrepresented in the overall global population, they accounted for 8 (10.3%) of the 78 participants enrolled in the United States.

Median time from randomization to data cutoff was 25.2 months (range, 7.5–50.6). In the pembrolizumab group, 396 participants received 1 dose of neoadjuvant therapy for a

Page 6

median of 4 cycles; of these, 325 (82.1%) underwent in-study surgery and 290 (73.2%) received 1 dose of adjuvant therapy (Fig. S2). In the placebo group, 399 participants received 1 dose of neoadjuvant therapy for a median of 4 cycles; of these, 317 (79.4%) underwent in-study surgery and 267 (66.9%) received 1 dose of adjuvant therapy (Fig. S2). Table S3 summarizes the reasons for not undergoing in-study surgery. The most common surgical procedure was lobectomy (Table S4). Among participants who underwent in-study surgery, 92.0% in the pembrolizumab group versus 84.2% in the placebo group had complete (R0) resection, 5.2% versus 9.8% had incomplete (R1) resection, 1.2% versus 1.3% had incomplete (R2) resection, and 1.5% versus 4.7% had unresectable tumors; median duration of the surgical hospital stay was 8.0 days (range, 1-50) versus 7.5 days (range, 1–65). Table S5 summarizes treatment exposure. In the intention-to-treat population, 17.1% of participants in the pembrolizumab group and 37.3% of participants in the placebo group received 1 subsequent systemic anticancer therapy, including 5.0% and 21.3%, respectively, who received subsequent immunotherapy.

Efficacy

344 (43.2%) participants had an event-free survival event, most commonly disease progression or recurrence (Table S6). The estimated percentage of participants alive without an event at 24 months was 62.4% (95% CI, 56.8–67.5) in the pembrolizumab group and 40.6% (95% CI, 34.8-46.3) in the placebo group. Median event-free survival was not reached (95% CI, 34.1 months to not reached) in the pembrolizumab group and was 17.0 months (95% CI, 14.3–22.0) in the placebo group (hazard ratio, 0.58; 95% CI, 0.46–0.72; P<0.00001) (Fig. 1A). The event-free survival benefit for pembrolizumab was generally consistent across all subgroups examined but some subgroups were small with a low number of events (Fig. 1B).

With 177 (22.2%) deaths, the estimated percentage of participants alive at 24 months was 80.9% (95% CI, 76.2–84.7) in the pembrolizumab group and 77.6% (95% CI, 72.5–81.9) in the placebo group (Fig. 2). Median overall survival was not reached in the pembrolizumab group and was 45.5 months in the placebo group. At this first interim analysis, the significance boundary was not crossed (P=0.02124). Restricted mean survival time at 48 months was 39.7 months and 36.6 months, respectively (difference, 3.1 months; 95% CI, 0.6-5.6). The between-group difference in overall survival measured by the hazard ratio is available in the Supplementary Results.

Major pathological response occurred in 120 (30.2%; 95% CI, 25.7–35.0) participants in the pembrolizumab group and 44 (11.0%; 95% CI, 8.1–14.5) participants in the placebo group (difference, 19.2; 95% CI, 13.9–24.7; P<0.00001). Pathological complete response occurred in 72 (18.1%; 95% CI, 14.5-22.3) participants in the pembrolizumab group and 16 (4.0%; 95% CI, 2.3–6.4) participants in the placebo group (difference, 14.2; 95% CI, 10.1– 18.7; P<0.00001). An exploratory analysis showed an event-free survival benefit for the pembrolizumab group regardless of whether participants had major pathological response (Fig. 3A) or pathological complete response (Fig. 3B).

Safety

Across all treatment phases in the as-treated population, treatment-related adverse events occurred in 96.7% of 396 participants in the pembrolizumab group and in 95.0% of 399 participants in the placebo group, including 44.9% and 37.3%, respectively, with grade 3 treatment-related adverse events and 17.7% and 14.3%, respectively, with serious treatmentrelated adverse events. The most common treatment-related adverse events in both groups were nausea, neutrophil count decreased, and anemia; the most common grade 3 treatmentrelated events were neutrophil count decreased, anemia, white blood cell count decreased, and platelet count decreased (Table 2). Treatment-related adverse events are summarized by treatment phase in Tables S7 and S8. Treatment-related adverse events led to death in 4 (1.0%) participants in the pembrolizumab group (n=1 each from immune-mediated lung disease, pneumonia, and sudden cardiac death during the neoadjuvant/surgery phase, n=1 from atrial fibrillation during the adjuvant phase) and in 3 (0.8%) participants in the placebo group (n=1 each from acute coronary syndrome, pneumonia, and pulmonary hemorrhage during the neoadjuvant/surgery phase). Treatment-related adverse events led to discontinuation of all study treatment in 12.6% of participants in the pembrolizumab group and 5.3% of participants in the placebo group. Among participants who underwent surgery, 71.1% in the pembrolizumab group and 71.3% in the placebo group experienced 1 adverse event of any cause during the surgical treatment phase, most commonly procedural pain (Table S9). Six (1.8%) participants in the pembrolizumab group and 2 (0.6%) in the placebo group died of any cause within 30 days after surgery; an additional 7 (2.2%) and 3 (0.9%)participants, respectively, died of any cause within 31–90 days after surgery (Table S10).

Potentially immune-mediated adverse events and infusion reactions occurred in 25.3% of participants in the pembrolizumab group and in 10.5% of participants in the placebo group(Table S11). These events were of grade 3 in 5.8% and 1.5% of participants, respectively. The most common potentially immune-mediated adverse events were hypothyroidism, hyperthyroidism, and pneumonitis in both the neoadjuvant/surgery and adjuvant treatment phases (Table S11). One participant died from a potentially immune-mediated adverse event (pneumonitis [recorded in the database as the aforementioned immune-mediated lung disease] in the pembrolizumab group).

Discussion

The randomized, placebo-controlled, phase 3 KEYNOTE-671 trial showed a significant improvement in event-free survival, major pathologic response, and complete pathologic response for neoadjuvant pembrolizumab plus cisplatin-based chemotherapy followed by surgical resection and adjuvant pembrolizumab compared with neoadjuvant chemotherapy and surgery alone. The overall survival benefit was not significant at this first interim analysis. Neoadjuvant pembrolizumab did not impact exposure to neoadjuvant chemotherapy or the choice of surgical approach, compromise the ability to undergo surgery, or increase surgical complications.

The event-free survival curves separated in favor of the pembrolizumab group by four months, and the hazard ratio for event-free survival was 0.58 (95% CI, 0.46-0.72; P<0.00001). 24-month event-free survival estimates were 62.4% in the pembrolizumab

group and 40.6% in the placebo group. The percentage of participants with major pathologic response was nearly tripled in the pembrolizumab group (30.2% vs 11.0% in the placebo group), and the percentage of participants with pathologic complete response was nearly quadrupled (18.1% vs 4.0%). Exploratory analysis showed an event-free survival benefit for the pembrolizumab group in participants with and without major pathologic response and in participants with and without pathologic complete response, suggesting that the adjuvant component of the regimen may provide benefit beyond that of neoadjuvant therapy and surgery alone. Additional analysis of KEYNOTE-671 and other trials, as well as future studies designed to directly answer the question, will be necessary to rule out other potential explanations and make definitive conclusions regarding the benefit of adjuvant immunotherapy after neoadjuvant chemoimmunotherapy, particularly in subsets defined by response to neoadjuvant treatment. Although cross-study comparisons should be done with caution given different designs and chemotherapy regimens, it is interesting to note that the hazard ratio for event-free survival in participants without pathological complete response was 0.84 (95% CI, 0.61-1.17) in CheckMate 816 and 0.69 (95% CI, 0.55-0.85) in KEYNOTE-671. Long-term data will help determine the relative benefit of perioperative versus neoadjuvant checkpoint inhibition.

The event-free survival benefit of pembrolizumab was generally consistent across all subgroups analyzed. Although participants with stage II disease and those who never smoked appeared to have less benefit with pembrolizumab, these subgroups were small with low event rates, leading to wide and overlapping confidence intervals. The benefit of pembrolizumab appeared similar in participants with squamous and nonsquamous histology. This is notable because several trials of checkpoint inhibitor-based regimens have shown that participants with nonsquamous histology have better outcomes than those with squamous histology.^{2,3,6,11–13} Molecular testing was not mandated in KEYNOTE-671, and very few participants with *EGFR* mutations or *ALK* translocations were identified, limiting any insights in these subgroups. The relative benefit in the pembrolizumab group increased with increasing PD-L1 expression (hazard ratio for event-free survival of 0.42 for PD-L1 tumor proportion score 50%, 0.51 for tumor proportion score 1–49%, and 0.77 for tumor proportion score <1%), but in all cases, the hazard ratio favored the pembrolizumab group and the 95% confidence intervals overlapped one another.

Results of the first interim analyses of two other placebo-controlled, phase 3 trials of perioperative checkpoint inhibition. In the global AEGEAN study, addition of perioperative durvalumab significantly improved event-free survival, major pathologic response, and pathologic complete response compared with neoadjuvant chemotherapy and surgery alone in resectable stage II-III NSCLC.¹⁸ In the Neotorch study conducted in China, addition of perioperative toripalimab significantly improved event-free survival, major pathologic response, and pathologic complete response compared with neoadjuvant chemotherapy and surgery alone in resectable stage III NSCLC.¹⁹ Although some differences are noted between the enrolled populations and designs of KEYNOTE-671, AEGEAN, and Neotorch, their findings taken together support the benefit of perioperative immune checkpoint inhibitor for resectable stage II-III NSCLC.

The safety profile of the combined regimen of pembrolizumab plus chemotherapy followed by surgery and adjuvant pembrolizumab was consistent with safety profiles of the individual medications, and no new safety signals were identified. The frequency of treatment-related serious adverse events was similar to that in previously reported studies of chemotherapy combined with checkpoint inhibitors,^{2,3} and the majority of reported adverse events are those associated with chemotherapy (e.g., anemia and nausea). The incidence and nature of immune-mediated adverse events in the pembrolizumab group was likewise consistent with prior reports. A low and comparable rate of deaths due to adverse events was seen in both treatment groups.

A limitation of the KEYNOTE-671 study design is that it does not permit direct analysis of the relative contributions of the neoadjuvant and adjuvant components of the treatment regimen. Such an analysis would have required a much larger sample size to accommodate two additional treatment groups—neoadjuvant pembrolizumab plus chemotherapy with adjuvant placebo and neoadjuvant placebo plus chemotherapy with adjuvant placebo. Similar to the other reported studies of perioperative^{18–20} and neoadjuvant¹¹ checkpoint inhibition, the follow-up duration is relatively short, limiting interpretation of long-term outcomes at this first interim analysis. While these other perioperative and neoadjuvant therapy to cisplatin-based regimens only.

In summary, the phase 3 KEYNOTE-671 trial demonstrated that the addition of pembrolizumab to neoadjuvant cisplatin-based chemotherapy followed by surgical resection and adjuvant pembrolizumab led to a significant improvement in event-free survival, major pathologic response, and pathologic complete response for participants with resectable stage II/III NSCLC.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank the patients and their families and caregivers for participating in the study; the investigators and site personnel; the independent data and safety monitoring committee; and the following employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA: Geri Lyn Ferraro, Ann Marie Mantz, and Andrea Rybak-Feiglin for study support; Gregory M. Lubiniecki for input into study design and study oversight; M. Catherine Pietanza for input into study design, study oversight, and critical review of the manuscript; Jin Zhang and Xuan Deng for statistical support; and Melanie A. Leiby for medical writing and editorial assistance.

Support

Supported by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. Jamie Chaft was additionally supported by a grant from the National Institutes of Health (P30 CA008748). HW, ML, TK, MT, S-HL, SG, KC, CD, MM, EE, GLM, OB, DR-A, JC, SN, and JDS received study funding to the institution from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA to support study conduct. HW, ML, TK, MT, S-HL, JH, SG, KC, CD, MM, EE, GLM, OB, DR-A, JC, SN, JY, SMK, AS, and JDS received medical writing and editorial support in preparation of this manuscript. JY, SMK, and AS report salary for full-time employment from Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. SMK and AS additionally report stock ownership in Merck & Co., Inc., Rahway, NJ, USA.

References

- 1. Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1positive non-small-cell lung cancer. N Engl J Med 2016;375:1823–33. [PubMed: 27718847]
- 2. Gandhi L, Rodriguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 2018;378:2078–92. [PubMed: 29658856]
- Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus chemotherapy for squamous non-smallcell lung cancer. N Engl J Med 2018;379:2040–51. [PubMed: 30280635]
- Hendriks LE, Kerr KM, Menis J, et al. Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2023;34:358–76. [PubMed: 36669645]
- NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines[®]:) Non-Small Cell Lung Cancer. Version 3.2023. 2023.
- Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage III non-smallcell lung cancer. N Engl J Med 2017;377:1919–29. [PubMed: 28885881]
- Antonia SJ, Villegas A, Daniel D, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med 2018;379:2342–50. [PubMed: 30280658]
- Forde PM, Chaft JE, Smith KN, et al. Neoadjuvant PD-1 blockade in resectable lung cancer. N Engl J Med 2018;378:1976–86. [PubMed: 29658848]
- Chaft JE, Oezkan F, Kris MG, et al. Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial. Nat Med 2022;28:2155–61. [PubMed: 36097216]
- Provencio M, Nadal E, Insa A, et al. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol 2020;21:1413–22. [PubMed: 32979984]
- Forde PM, Spicer J, Lu S, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med 2022;386:1973–85. [PubMed: 35403841]
- Felip E, Altorki N, Zhou C, et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet 2021;398:1344–57. [PubMed: 34555333]
- O'Brien M, Paz-Ares L, Marreaud S, et al. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial. Lancet Oncol 2022;23:1274–86. [PubMed: 36108662]
- 14. Brierly JD, Gospodarowicz MK, Wittekind C. TNM Classification of Malignant Tumors. Eighth Edition. Oxford, UK: John Wiley & Sons; 2016.
- Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649–55. [PubMed: 7165009]
- Zhao L, Claggett B, Tian L, et al. On the restricted mean survival time curve in survival analysis. Biometrics 2016;72:215–21. [PubMed: 26302239]
- 17. Maurer W, Bretz F. Multiple testing in group sequential trials using graphical approaches. Stat Biopharm Res 2013;5:311–20.
- Heymach JV, Harpole D, Mitsudomi T, et al. CT005: AEGEAN: a phase 3 trial of neoadjvuant durvalumab + chemotherpy followed by adjvuant durvalumab in patients with resectable NSCLC. Abstract presented at: AACR Annual Meeting 2023; April 14–19, 2023; Orlando, FL.
- 19. Lu S, Wu L, Zhang W, et al. Perioperative toripalimab + platinum-doublet chemotherapy vs chemotherapy in resectable stage II/III non-small cell lung cancer (NSCLC): interim event-free survival (EFS) analysis of the phase III Neotorch study. J Clin Oncol 2023;41:425126.
- 20. Provencio-Pulla M, Nadal E, Larriba JLG, et al. Nivolumab plus chemotherapy versus chemotherapy as neoadjuvant treatment for resectable stage IIIA NSCLC: Primary endpoint results of pathological complete response (pCR) from phase II NADIM II trial. J Clin Oncol 2022;40:8501.

Model 139/397 205/400 Hazard Ratio for Event or Death (95% C1) 0.5% (0.46-0.72) All patients 139/397 205/400 40.20 40.33 (0.39-0.71) Subgroup 139/177 205/400 40.40 40.40 40.40 All patients 139/377 205/400 40.40	A Event-free Survival										
Image: space		100	lie.								
B 000000000000000000000000000000000000	-	90-	June								
Pertoclizuma group Perto	%	80-	all alle								
Vo. at Risk Permbrolizumab group Phacebo group Placebo group Placebo group No. at Risk Permbrolizumab group 397 330 236 172 117 72 42 1 0 0 B Subgroup Analysis of Event-free Survival Pacebo group Permbrolizumab group 397 330 236 172 117 72 42 1 0 0 B Subgroup Analysis of Event-free Survival Group Permbrolizumab group Permbrolizumab group 0.58 0.640-0.72) Age 57 74/221 113/214 0 0.55 0.640-0.72) Age 0.51/16 92/186 0.64 0.620-0.80 0.64 0.620-0.80 Sex 65/176 92/186 0.64 0.620-0.80 0.64 0.620-0.80 Male 108/279 150/284 0 0.65 0.64 0.620-0.80 0.64 0.620-0.80 Geographic region 83/280 123/235 0 0.65 0.64 0.627-0.31 0.55 0.57 0.54 0.64	val	70-	-	Lilly and the	L. Malan	Non I S I S					
Sec Perror 0.58 (0.46-0.72) Age	ivi	60-		and		and the second s	Line in	and the second		Pemt	rolizumab group
9 00- 0-0- 0-0- 0-0-0-0-0-0-0-0-0-0-0-0-0	S SI	50-			- les	ul,				- reme	ionzumao group
g 00- 0- 0- 0- 0- 0- 0- 0- 0- 0- 0- 0- 0-	free	40-				de la					
3 20- 10- 0- 0- 0- 6 12 18 24 30 36 42 48 54 No. at Risk Pembrolizumab group Phicebo group 397 330 236 172 117 72 42 11 0 0 B Subgroup Analysis of Events/ne. of participants Hazard Ratio for Event or Death (95% C1) Croup no. of participants All patients 139/397 205/400 0.58 (0.46-0.72) Age 0.58 (0.46-0.72) Age 0.58 (0.46-0.72) Age 0.58 (0.46-0.72) Age 0.58 (0.46-0.72) 0.58 (0.46-0.72) 0.58 (0.46-0.72) 0.58 (0.46-0.72) 0.58 (0.46-0.72) Age 0.58 (0.46-0.72) 0.58 (0.46-0.88) 0.58 (0.46-0.89) 0.58 (0.46-0.80) 0.58 (0.46-0.80) 0.58 (0.46-0.80) 0.58 (0.46-0.80) 0.58 (0.46-0.80) 0.51 (0.41-0.72) 0.54 (0.41-0.62) 0.54 (0.41-0.62)	ut-	30-								P P	Placebo group
10- 0 - 6 12 18 24 30 36 42 48 54 Months No. at Risk Pembrolizumab group 397 330 236 172 117 72 42 11 0 0 B Subgroup Analysis of Event-free Survival Subgroup Pembrolizumab of centri/no. of participants Hacard Ratio for Event or Death (95% CI) All patients 139/397 205/400 0.58 (0.46-0.72) -0.58 (0.46-0.38) 0.58 (0.46-0.38) 0.58 (0.46-0.38) 0.58 (0.46-0.38) 0.58 (0.46-0.38) 0.58 (0.46-0.38) 0.58 (0.46-0.38) 0.58 (0.46-0.38) 0.58 (0.46-0.38) 0.53 (0.40-0.80) -0.57 (0.43-0.37) 0.53 (0.40-0.80) Male 108/279 0.54 (0.41-0.72) 0.54 (0.41-0.72) 0.54 (0.41-0.72) 0.54 (0.41-0.69) Smoking status Current smoker 96/271 152/279 -0.57 (0.43-0.73) 0.57 (0.43-0.73) 0.57 (0.43-0.73) 0.57 (0.43-0.73) 0.57 (0.43-0.73) 0.57 (0.43-0.73) 0.57 (0.43-0.73) 0.58 (0.43-0.39) 0.57 (0.43-0.73) 0.57 (0.43-0.73) 0.57 (0.43-0.73) 0.57 (0.43-0.73) 0.57 (0.43-0.73) 0.57 (0.43-0.73) 0.57 (0.43-0.73) 0.57 (0.43-0.73)	Eve	20-									
01 6 12 18 24 30 36 42 48 54 Months No. at Risk Pembrolizumab group A00 397 330 236 172 117 72 42 11 0 0 Biogroup Analysis of Event-free Survival Bougroup Pembrolizumab Group no. of events/no. of participants All patients 139/397 205/400 42 42 42 42 42 43 44 44 44 44 45 45 42 42 42 42 42 42 42 43 44 44 44 44 45 45 45 45 45 45 46 47 48 47 42 48 48 48 49 44 46 47 48 47 48 47 48 47 48 48<		10-									
No. at Risk Perabolizumab group Placebo group 397 330 236 1/2 1/7 7/2 4/2 1/1 0 0 B Subgroup Analysis of Event-free Survival Subgroup Permbrolizumab Group no. of events/no. of participants Pacebo Forup no. of events/no. of participants Hazard Ratio for Event or Death (95% CI) 0.58 (0.46-0.72) Age softy 5/1/6 92/186 → 0.58 (0.46-0.72) Age 		0+	6	12	18	24	30	36	42	18	54
No. at Risk Pernbrolizumab group 397 330 236 172 117 72 42 11 0 0 B Subgroup Analysis of Event-free Survival Subgroup Placebo Group Placebo Group Placebo Group Placebo Group Hazard Ratio for Event or Death (95% CI) All patients 139/397 205/400 0.58 (0.46–0.72) ac6 5y 74/221 113/214 0.53 (0.39–0.71) ac6 5y 74/221 139/37 205/244 0.64 (0.46–0.88) 0.63 (0.49–0.80) Race White 85/250 150/284 0.63 (0.49–0.80) 0.64 (0.41–0.72) 0.66 (0.45–0.99) 0.61 (0.42–0.08) Geographic region East Asia 43/123 57/123 0.52 (0.44–0.78) 0.52 (0.44–0.78) 0.57 (0.41–0.77) 0.58 (0.43–0.78) 0.58 (0.43–0.78) 0.58 (0.43–0.78) 0.57 (0.41–0.77) 0.58 (0.43–0.78) 0.57 (0.41–0.77)		0	0	12	10	24	50	50	42	40	54
No. at Risk Permbolizumab group 397 330 236 172 117 72 42 11 0 0 Placebo group 400 294 183 124 74 38 24 9 1 0 B Subgroup Analysis of Event-free Survival co. of events/no. of participants Permbrolizumab Placebo Group Group Group no. of events/no. of participants Placebo (95% CI) 0.58 (0.46-0.72) Age						Mor	iths				
Permbrolizumab group 397 330 236 172 117 72 42 11 0 0 Placebo group 400 294 183 124 74 38 24 9 1 0 B Subgroup Analysis of Event-free Survival Group Pacebo Group Group no. of events/no. of participants Hazard Ratio for Event or Death (95% CI) Hazard Ratio for Event or Death (95% CI) All patients 139/397 205/400 → 0.58 (0.46–0.72) Age - 0.58 (0.46–0.72) - 0.58 (0.46–0.72) Sex - 0.64 (0.46–0.88) - Female 31/18 55/116 - 0.64 (0.46–0.88) Male 108/270 0.63 (0.49–0.80) 0.63 (0.49–0.80) Geographic region - 0.52 (0.42–0.89) - 0.65 (0.42–0.89) Other 96/274 148/279 - 0.52 (0.34–0.78) Gurrent smoker 37/96 57/103 - 0.53 (0.42–0.79) Other 96/274 <th< td=""><td>No. at Risk</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></th<>	No. at Risk										
Placebo group 400 294 183 124 74 38 24 9 1 0 B Subgroup Analysis of Event/rec Survival Subgroup Permbrolizumab Group no. of events/no. of participants Hazard Ratio for Event or Death (9% CI) Hazard Ratio for Event or Death (9% CI) All patients 139/397 205/400 0.58 (0.46-0.72) Age 0.53 (0.39-0.71) 265 yr 65/176 92/186 0.64 (0.46-0.88) Sex Fernale 108/279 150/284 0.64 (0.46-0.89) 0.64 (0.47-0.89) 0.66 (0.45-0.99) 0.66 (0.45-0.99) 0.66 (0.45-0.99) 0.66 (0.45-0.99) 0.66 (0.45-0.99) 0.66 (0.45-0.99) 0.66 (0.45-0.79) 0.66 (0.45-0.79) 95/121 0.66 (0.45-0.79) 0.65 (0.42-0.70) 0.65 (0.42-0.70) 0.65 (0.42-0.70) 0.66 (0.45-0.79) 0.66 (0.45-0.99) 0.77 (0.41 - 0.71) 0.65 (0.42-0.10) 111 34/118 48/121 0.57 (0.41 - 0.71) 0.58 (0.42 - 0.73) 0.54 (0.42 - 0.73) 0.54 (0.42 - 0.73) 0.54 (0.42 - 0.73) 0.55 (0.42 - 0.10) <	Pembrolizumab group	397	330	236	172	117	72	42	11	0	0
B Subgroup Analysis of Event-free Survival Group no. of events/no. of porticipants Hazard Ratio for Event or Death (95% CI) All patients 139/397 205/400 	Placebo group	400	294	183	124	74	38	24	9	1	0
B Jugroup Analysis of Event Hee Survival Subgroup	Del di		- · ·								
Permbrolizumab Placebo Hazard Ratio for Event or Death Subgroup Group Group (95% CI) All patients 139/397 205/400 ● 0.58 (0.46–0.72) Age - 0.53 (0.39–0.71) 265 yr 74/221 113/214 ● 0.53 (0.39–0.71) 265 yr 65/1/6 92/186 ● 0.64 (0.46–0.88) Sex - 0.64 (0.46–0.88) 0.63 (0.49–0.80) Sex - 0.54 (0.41–0.72) 0.62 (0.42–0.89) Geographic region - 0.66 (0.45–0.99) 0.66 (0.45–0.99) East Asia 43/123 57/121 ● 0.66 (0.45–0.99) Other 96/274 148/279 ● 0.57 (0.43–0.78) Smoking stus - 0.55 (0.42–1.01) 0.55 (0.42–0.78) Current smoker 37/95 57/103 ● 0.57 (0.43–0.78) Nonsquamous 73/226 107/227 ● 0.55 (0.42–0.79) Squamous 66/171 98/173 ● 0.57 (0.41–0.77)	B Subgroup Analysis of	Event-free	Survival								
Subgroup Group Group Group (55% CI) no. of events/no. of participants 139/397 205/400 ● 0.58 (0.46-0.72) Age - 0.53 (0.39-0.71) 265 yr 65/176 92/186 ● 0.64 (0.46-0.88) Sex Female 31/118 55/116 ● 0.64 (0.46-0.88) Male 108/279 150/284 ● 0.63 (0.49-0.80) Race - 0.54 (0.41-0.72) 0.66 (0.42-0.89) Other 46/134 70/145 ● 0.66 (0.42-0.89) Geographic region - 0.66 (0.42-0.89) 0.64 (0.42-0.72) Current smoker 34/123 57/121 ● 0.66 (0.42-0.72) Somking status - - 0.52 (0.34-0.78) Former smoked 18/54 20/47 ● 0.56 (0.42-0.70) Pathologic features - 0.57 (0.43-0.75) 0.54 (0.42-0.70) Nonsquamous 73/225 107/227 ● 0.54 (0.42-0.70) Pathologic features - <		Pembro	lizumab	Placebo			Ha	azard Rati	o for Eve	nt or Dea	ath
no. of participants Age <65 yr	Subgroup	Gr	oup	Group					(95% CI)		
All patients 139/397 205/400 ◆ 0.58 (0.46-0.72) Age 0.53 (0.39-0.71) 265 yr 65 (1/5 92/186 0.64 (0.46-0.88) Sex 0.63 (0.49-0.80) 0.64 (0.46-0.88) 0.63 (0.49-0.80) Race 0.54 (0.41-0.72) 0.65 (0.49-0.80) 0.63 (0.49-0.80) White 85/250 123/239 ◆ 0.66 (0.45-0.99) Other 96/274 148/279 0.54 (0.41-0.69) Smoking status 0.52 (0.34-0.78) Current smoker 31/118 48/121 ● 0.65 (0.42-0.72) Never smoked 13/54 20/47 ● 0.52 (0.34-0.78) Squamous 66/171 98/173 ● 0.58 (0.42-0.70) Squamous 66/171 98/173 ●		no. of e	events/no.	of participan	ts						
Age -65 yr 74/221 113/214 → 0.53 (0.39-0.71) 265 yr 65/176 92/186 → 0.64 (0.46-0.88) Sex - 0.64 (0.46-0.88) - 0.63 (0.49-0.80) Race - 0.54 (0.41-0.72) 0ther 40.62 (0.42-0.89) White 85/250 123/239 → 0.54 (0.41-0.72) Other 46/134 70/145 → 0.66 (0.45-0.99) Geographic region - 0.57 (0.43-0.75) 0.57 (0.43-0.75) East Asia 43/123 57/103 → 0.57 (0.43-0.75) Somoking status - 0.57 (0.43-0.75) 0.57 (0.43-0.75) Current smoker 37/96 57/103 → 0.57 (0.43-0.75) Never smoked 18/54 20/47 → 0.58 (0.43-0.78) Pathological stage - 0.58 (0.43-0.78) 0.53 (0.42-0.70) III 105/279 157/279 → 0.58 (0.42-0.70) Squamous 73/226 107/227 → 0.58 (0.43-0.78) Squamous 61/11 98/173 → 0.42 (0.28-0	All patients	139	/397	205/400					+		0.58 (0.46-0.72)
<65 yr	Age										
abs yr 65/176 92/186 ● 0.64 (0.46-0.88) Female 31/118 55/116 ● 0.63 (0.49-0.80) Male 108/229 150/284 ● 0.63 (0.49-0.80) White 85/250 123/239 ● 0.62 (0.42-0.89) Geographic region ● ● 0.66 (0.45-0.99) East Asia 43/123 57/121 ● 0.66 (0.45-0.99) Other 96/274 148/279 ● 0.52 (0.34-0.78) Former smoker 37/96 57/103 ● 0.57 (0.43-0.75) Never smoked 18/54 20/47 ● 0.57 (0.43-0.75) Never smoked 18/54 20/47 ● 0.53 (0.42-0.70) Hit 34/118 48/121 ● 0.55 (0.42-0.70) Hitstologic features ● 0.57 (0.41-0.77) 0.54 (0.42-0.70) Nonsquamous 66/171 98/173 ● 0.57 (0.41-0.77) PD-L1 TPS (50% cutoff) ● 0.57 (0.41-0.77) 0.57 (0.41-0.77) 107/265 142/266 ● 0.77 (0.55-1.07) 0.57 (0.41-0.77) </td <td><65 yr</td> <td>74</td> <td>/221</td> <td>113/214</td> <td></td> <td></td> <td></td> <td>-</td> <td>•</td> <td></td> <td>0.53 (0.39-0.71)</td>	<65 yr	74	/221	113/214				-	•		0.53 (0.39-0.71)
Sex Female 31/118 55/116 \rightarrow 0.44 (0.28-0.68) Male 108/279 150/284 \rightarrow 0.63 (0.49-0.80) Race \rightarrow 0.62 (0.42-0.89) Geographic region \rightarrow 0.54 (0.41-0.72) Other 46/134 70/145 \rightarrow 0.62 (0.42-0.89) Geographic region \rightarrow 0.54 (0.41-0.69) Smoking status \rightarrow 0.54 (0.41-0.69) Smoking status \rightarrow 0.52 (0.34-0.78) Former smoker 37/96 57/103 \rightarrow 0.52 (0.34-0.78) Never smoked 18/54 20/47 \rightarrow 0.68 (0.36-1.30) Pathological stage \rightarrow 0.52 (0.34-0.78) Nonsquamous 73/226 107/227 \rightarrow 0.58 (0.42-0.10) III 34/118 48/121 \rightarrow 0.65 (0.42-1.01) III 005/279 157/279 \rightarrow 0.54 (0.41-0.67) Squamous 66/171 98/173 \rightarrow 0.57 (0.41-0.77) PD-L1 TPS (50% cutoff) <50% 32/132 63/134 \rightarrow 0.42 (0.28-0.65) PD-L1 TPS (\rightarrow 0.64 (0.49-0.82) $a 50\%$ 32/132 63/134 \rightarrow 0.42 (0.28-0.65) PD-L1 TPS (\rightarrow 0.47 (0.36-0.63) PD-L1 TPS (\rightarrow 0.48 (0.31-0.74) $a 50\%$ 32/132 63/134 \rightarrow 0.42 (0.28-0.65) EGFR mutation \rightarrow 0.43 (0.31-0.74) Yes 1/14 10/19 \rightarrow 0.48 (0.31-0.74) Yes 1/14 10/19 \rightarrow 0.48 (0.31-0.74) Yes 1/14 10/19 \rightarrow 0.48 (0.31-0.74) No 29/104 76/133 \rightarrow 0.41 (0.26-0.62) No 0 29/104 76/133 \rightarrow 0.41 (0.26-0.62) a 0.10 0.20 0.50 1.00 3.00 Paebrolizumab Better Placebo Better	≥65 yr	65	/176	92/186					-		0.64 (0.46-0.88)
Premate 33/118 35/118 → 0.44 (0.28-0.68) Male 108/279 150/284 → 0.63 (0.49-0.80) Race 0.014 0.02 0.54 (0.41-0.72) 0.66 (0.45-0.99) Other 46/134 70/145 → 0.66 (0.45-0.99) Geographic region 0.54 (0.41-0.69) 0.57 (0.43-0.75) East Asia 43/123 57/103 → 0.52 (0.34-0.78) Former smoker 37/96 57/103 → 0.52 (0.34-0.78) Former smoker 38/54 20/47 → 0.58 (0.43-0.78) Pathological stage 0.57 (0.41-0.72) → 0.58 (0.42-1.01) III 105/279 157/279 → 0.54 (0.42-0.70) Histologic features Nonsquamous 73/226 107/227 → 0.58 (0.43-0.78) Squamous 63/138 80/151 → 0.57 (0.41-0.72) 0.58 (0.43-0.78) Systematic features 107/227 → 0.58 (0.43-0.78) 0.57 (0.41-0.72) PD-L1 TPS (1% cutoff) - - 0.64 (0.49-0.82) 25% 0.57 (0.45-1.07) 1.40 (0.26-0.6	Sex	21	(110	55 (11)							0.44.(0.280.68)
Nate 100/275 100/264 0.03 (0.9-0.80) Race 0.05 (0.9-0.80) 0.54 (0.41-0.72) 0.62 (0.42-0.89) Geographic region 0.62 (0.42-0.89) 0.62 (0.42-0.89) East Asia 43/123 57/121	Female	109	/118	150/284				-			0.44 (0.28-0.68)
Nate 85/250 123/239 \bullet 0.54 (0.41-0.72) Other 46/134 70/145 \bullet 0.62 (0.42-0.89) Geographic region \bullet 0.66 (0.45-0.99) 0ther East Asia 43/123 57/121 \bullet 0.66 (0.45-0.99) Other 96/274 148/279 \bullet 0.54 (0.41-0.69) Smoking status \bullet 0.52 (0.34-0.78) 0.68 (0.36-1.30) Current smoker 84/247 128/250 \bullet 0.66 (0.42-0.01) Pathological stage \bullet 0.51 (0.43-0.75) 0.68 (0.36-1.30) Pathological stage \bullet 0.54 (0.42-0.70) \bullet 0.54 (0.42-0.70) Histologic features \bullet 0.51 (0.42-0.70) \bullet 0.54 (0.42-0.70) Nonsquamous 66/171 98/173 \bullet 0.57 (0.41-0.77) PD-L1 TPS (50% cutoff) \bullet 0.54 (0.42-0.61) \bullet 0.64 (0.49-0.82) 250% 32/132 63/134 \bullet 0.42 (0.28-0.65) PD-L1 TPS (1% cutoff) \bullet 0.47 (0.55-1.07) $c1\%$ 63/138 80/151 \bullet 0.77 (0.55-1.	Pace	108	1219	130/204							0.03 (0.49-0.80)
Other 46/134 70/145 0.62 (0.42-0.89) Geographic region 57/121 0.66 (0.45-0.99) East Asia 43/123 57/121 0.66 (0.45-0.99) Other 96/274 148/279 0.52 (0.34-0.78) Smoking status 0.52 (0.34-0.78) 0.57 (0.43-0.75) Current smoker 37/96 57/103 0.55 (0.43-0.75) Former smoker 84/247 128/250 0.66 (0.42-0.10) II 34/118 48/121 0.65 (0.42-1.01) III 105/279 157/279 0.58 (0.43-0.78) Nonsquamous 73/226 107/227 0.58 (0.43-0.78) Squamous 66/171 98/173 0.57 (0.41-0.77) PD-L1 TPS (50% cutoff) - 0.57 (0.41-0.77) <50%	White	85	/250	123/239				-			0.54 (0.41-0.72)
Geographic region 0.66 (0.45-0.99) East Asia 43/123 57/121 Other 96/274 148/279 Smoking status 0.54 (0.41-0.69) Current smoker 37/96 57/103 Former smoker 34/247 128/250 Never smoked 18/54 20/47 II 34/118 48/121 II 105/279 157/279 Histologic features 0.55 (0.42-0.70) Nonsquamous 73/226 0.57 (0.41-0.78) Squamous 66/171 98/173 <	Other	46	/134	70/145					-		0.62 (0.42-0.89)
East Asia 43/123 57/121 - 0.66 (0.45-0.99) Other 96/274 148/279 0.54 (0.41-0.69) Smoking staus 0.52 (0.34-0.78) 0.57 (0.43-0.75) Current smoker 84/247 128/250 - 0.56 (0.42-0.78) Pormer smoker 84/247 128/250 - 0.57 (0.43-0.75) Never smoked 18/54 20/47 - 0.66 (0.42-0.10) III 105/279 157/279 - 0.58 (0.43-0.78) Pathologic features - 0.51 (0.42-0.70) 0.54 (0.42-0.70) Nonsquamous 73/226 107/227 - 0.58 (0.43-0.78) Squamous 66/171 98/173 - 0.57 (0.41-0.77) PD-L1 TPS (50% cutoff) - - 0.64 (0.49-0.82) 250% 250% 32/132 63/138 80/151 - 0.77 (0.55-1.07) 21% 63/138 80/151 - 0.51 (0.34-0.75) 250% 250% 32/132 63/134 - 0.47 (0.36-0.63) 20.77 (0.55-1.07) 1-49% 0.51 (0.34-0.75) 250% 32/132	Geographic region		/								(
Other 96/274 148/279 \bullet 0.54 (0.41-0.69) Smoking status 0.52 (0.34-0.78) 0.52 (0.34-0.78) Current smoker 37/96 57/103 \bullet 0.52 (0.34-0.78) Former smoked 18/54 20/47 0.668 (0.36-1.30) Pathological stage 0.51 (0.42-0.01) 0.668 (0.36-1.30) II 34/118 48/121 \bullet 0.65 (0.42-1.01) III 105/279 157/279 \bullet 0.58 (0.43-0.78) Squamous 66/171 98/173 \bullet 0.57 (0.41-0.77) PD-L1 TPS (50% cutoff) $<$ $0.57 (0.41-0.77)$ $0.57 (0.41-0.77)$ <50%	East Asia	43	/123	57/121					-		0.66 (0.45-0.99)
Smoking status Gurrent smoker $37/96$ $57/103$ → 0.52 (0.34–0.78) Former smoker $84/247$ $128/250$ → 0.57 (0.43–0.78) Never smoked $18/54$ $20/47$ → 0.65 (0.42–1.01) II $34/118$ $48/121$ → 0.65 (0.42–0.70) Histologic features Nonsquamous $73/226$ $107/227$ → 0.58 (0.42–0.70) Histologic features Nonsquamous $66/171$ $98/173$ → 0.57 (0.41–0.77) PD-L1 TPS (50% cutoff) - 0.57 (0.41–0.77) 0.42 (0.28–0.65) >50% $32/132$ $63/134$ → 0.42 (0.28–0.65) PD-L1 TPS (1% cutoff) - 0.47 (0.35–1.07) 2.1% 0.47 (0.35–0.63) PD-L1 TPS 63/138 $80/151$ → 0.77 (0.55–1.07) 21% $63/138$ $80/151$ → 0.77 (0.55–1.07) 21% $63/138$ $80/151$ → 0.42 (0.28–0.65) EGFR mutation - 0.42 (0.28–0.65) 0.42 (0.28–0.65) No $31/111$ $64/127$ </td <td>Other</td> <td>96</td> <td>/274</td> <td>148/279</td> <td></td> <td></td> <td></td> <td>-</td> <td>+</td> <td></td> <td>0.54 (0.41-0.69)</td>	Other	96	/274	148/279				-	+		0.54 (0.41-0.69)
Current smoker $37/96$ $57/103$ \bullet $0.52 (0.34-0.78)$ Former smoker $84/247$ $128/250$ \bullet $0.57 (0.43-0.78)$ Never smoked $18/54$ $20/47$ $0.68 (0.36-1.30)$ Pathological stage $0.57 (0.43-0.78)$ $0.68 (0.36-1.30)$ II $34/118$ $48/121$ \bullet $0.65 (0.42-0.70)$ Histologic features $0.57 (0.41-0.77)$ $0.54 (0.42-0.70)$ Squamous $73/226$ $107/227$ \bullet $0.58 (0.43-0.78)$ Squamous $66/171$ $98/173$ \bullet $0.57 (0.41-0.77)$ PD-L1 TPS (50% cutoff) $<$ $0.57 (0.41-0.77)$ $0.57 (0.41-0.77)$ 50% $107/265$ $142/266$ \bullet $0.64 (0.49-0.82)$ $\geq 50\%$ $32/132$ $63/138$ $80/151$ $0.77 (0.55-1.07)$ $\sim 1\%$ $63/138$ $80/151$ $0.77 (0.55-1.07)$ $\sim 1\%$ $63/138$ $80/151$ $0.77 (0.55-1.07)$ $\sim 1\%$ $63/138$ $80/151$ $0.47 (0.36-0.63)$ PD-L1 TPS 50% $32/132 - 63/134$ $0.42 (0.28-0.65)$ <	Smoking status								1		
Former smoker $84/247$ $128/250$ \bullet 0.57 ($0.43-0.75$) Never smoked $18/54$ $20/47$ \bullet 0.68 ($0.36-1.30$) Pathological stage 0.57 ($0.43-0.75$) 0.68 ($0.36-1.30$) II $105/279$ $157/279$ \bullet 0.55 ($0.42-0.70$) Histologic features 0.57 ($0.43-0.78$) 0.54 ($0.42-0.70$) Nonsquamous $73/226$ $107/227$ \bullet 0.58 ($0.43-0.78$) Squamous $66/171$ $98/173$ \bullet 0.57 ($0.41-0.77$) PD-L1 TPS (50% cutoff) <0.57 ($0.41-0.77$) 0.58 ($0.43-0.78$) 0.57 ($0.41-0.77$) 250% $32/132$ $63/134$ \bullet 0.42 ($0.28-0.65$) PD-L1 TPS (3% $63/138$ $80/151$ \bullet 0.77 ($0.55-1.07$) 21% $63/138$ $80/151$ \bullet 0.77 ($0.55-1.07$) 21% $63/138$ $80/151$ \bullet 0.77 ($0.55-1.07$) $2-19\%$ $32/132$ $63/138$ $80/151$ \bullet 0.44 ($0.28-0.65$) <i>EGFR</i> mutation No $31/111$ $64/127$ \bullet	Current smoker	37	/96	57/103					← :		0.52 (0.34-0.78)
Never smoked 18/54 20/47 $0.68 (0.36-1.30)$ Pathological stage 0.65 (0.42-1.01) 0.65 (0.42-1.01) II 105/279 157/279 $0.54 (0.42-0.70)$ Histologic features 0.55 (0.42-0.70) 0.58 (0.43-0.78) Squamous 66/171 98/173 $0.57 (0.41-0.77)$ PD-L1 TPS (50% cutoff) $0.57 (0.51-0.7)$ $0.64 (0.49-0.82)$ $< 50\%$ 32/132 63/134 $0.42 (0.28-0.65)$ PD-L1 TPS (1% cutoff) $0.47 (0.36-0.63)$ $0.47 (0.36-0.63)$ $< 11\%$ 63/138 80/151 $0.47 (0.36-0.63)$ PD-L1 TPS $76/259$ 125/249 $0.47 (0.36-0.63)$ $< 11\%$ 63/138 80/151 $0.47 (0.36-0.63)$ $< 11\%$ 63/138 80/151 $0.47 (0.36-0.63)$ $< 15\%$ 32/132 63/134 $0.47 (0.36-0.63)$ $S50\%$ 32/132 63/134 $0.47 (0.36-0.63)$ $< 15\%$ $0.47 (0.36-0.63)$ $0.47 (0.36-0.63)$ $< 15\%$ $0.41 (0.26-0.62)$ $0.64 (0.49-0.83)$ $< 40\%$ $0.11 (0.19 (0.20 (0.50 (1.00 (0.64 (0.49-0.82)))))$ $0.64 (0.49-0.82)$	Former smoker	84	/247	128/250					•		0.57 (0.43-0.75)
Pathological stage II 34/118 48/121 → 0.65 (0.42-1.01) III 105/279 157/279 → 0.54 (0.42-0.70) Histologic features Nonsquamous 73/226 107/227 → 0.58 (0.43-0.78) Squamous 66/171 98/173 → 0.57 (0.41-0.77) PD-L1 TPS (50% cutoff) <50% 32/132 63/134 → 0.42 (0.28-0.65) PD-L1 TPS (1% cutoff) <1% 63/138 80/151 → 0.77 (0.55-1.07) ≥1% 76/259 125/249 → 0.47 (0.36-0.63) PD-L1 TPS <1% 63/138 80/151 → 0.77 (0.55-1.07) ≥1% 76/259 2125/249 → 0.47 (0.36-0.63) PD-L1 TPS <1% 63/138 80/151 → 0.77 (0.55-1.07) ≥50% 32/132 63/134 → 0.42 (0.28-0.65) EGFR mutation No 31/111 64/127 → 0.51 (0.34-0.75) ≥50% 21/12 62/115 → 0.51 (0.34-0.75) ≥50% 32/132 63/134 → 0.42 (0.28-0.65) EGFR mutation No 31/111 64/127 → 0.48 (0.31-0.74) Yes 1/14 10/19 → 0.09 (0.01-0.74) Unknown 107/272 131/254 → 0.64 (0.49-0.82) 0.01 0.10 0.20 0.50 1.00 3.00 Pembrolizumab Better Placebo Better	Never smoked	18	/54	20/47					•		0.68 (0.36-1.30)
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Pathological stage	24	/110	40/101							0 (5 (0 42 1 01)
III 103/279 137/279 → 0.34 (0.42-0.70) Histologic features Nonsquamous 73/226 107/227 → 0.58 (0.43-0.78) Squamous 66/171 98/173 → 0.57 (0.41-0.77) PD-L1 TPS (50% cutoff) - 0.64 (0.49-0.82) 0.57 (0.41-0.77) ≥50% 32/132 63/134 → 0.42 (0.28-0.65) PD-L1 TPS (1% cutoff) - - 0.77 (0.55-1.07) ≥1% 63/138 80/151 → 0.77 (0.55-1.07) ≥1% 63/138 80/151 → 0.77 (0.55-1.07) ≥1% 63/138 80/151 → 0.44 (0.28-0.65) PD-L1 TPS - 0.51 (0.34-0.75) 250% 32/132 63/134 PD-L3 - - 0.77 (0.55-1.07) 0.51 (0.34-0.75) 250% 32/132 63/134 → 0.42 (0.28-0.65) EGFR mutation - - 0.51 (0.34-0.75) 250% 0.22 (0.28-0.65) 0.43 (0.31-0.74) 0.64 (0.49-0.83) Ves 1/14 10/19 - 0.64 (0.49-0.83) 0.64 (0.49-0.82) 0.63 (105	/118	48/121							0.65 (0.42 - 1.01)
Nonsquamous 73/226 107/227 0.58 (0.43-0.78) Squamous 66/171 98/173 0.57 (0.41-0.77) PD-L1 TPS (50% cutoff) 0.58 (0.43-0.78) 0.57 (0.41-0.77) <50%	Histologic features	105	1219	137/279							0.34 (0.42-0.70)
Squamous 66/171 98/173 ● 0.57 (0.41-0.77) PD-L1 TPS (50% cutoff) - 0.64 (0.49-0.82) 250% ≥50% 32/132 63/134 ● 0.42 (0.28-0.65) PD-L1 TPS (1% cutoff) - 0.77 (0.55-1.07) 0.47 (0.36-0.63) ≥1% 63/138 80/151 ● 0.47 (0.36-0.63) PD-L1 TPS - 0.77 (0.55-1.07) 0.47 (0.36-0.63) ≥1% 63/138 80/151 ● 0.47 (0.36-0.63) PD-L1 TPS - 0.57 (0.41-0.77) 0.55-1.07) ≥50% 32/132 63/134 ● 0.47 (0.36-0.63) PD-L1 TPS - 0.51 (0.34-0.75) 0.55 (0.34-0.75) ≥50% 32/132 63/134 ● 0.42 (0.28-0.65) EGFR mutation - 0.42 (0.28-0.65) 0.63 (0.49-0.83) ALK translocation - 0.48 (0.31-0.74) 0.64 (0.49-0.83) No 29/104 76/133 ● 0.41 (0.26-0.62) 0.63 (0.49-0.82) Unknown 106/281 128/258 ● 0.10 0.00 0.60 (0.49-0.82) 0.63 (Nonsquamous	73	/226	107/227					- i -		0.58 (0.43-0.78)
PD-L1 TPS (50% cutoff) $\leq 50\%$ 107/265 142/266 \rightarrow 0.64 (0.49-0.82) $\geq 50\%$ 32/132 63/134 \rightarrow 0.42 (0.28-0.65) PD-L1 TPS (1% cutoff) $< 1\%$ 63/138 80/151 \rightarrow 0.77 (0.55-1.07) $\geq 1\%$ 76/259 125/249 \rightarrow 0.47 (0.36-0.63) PD-L1 TPS $< 1\%$ 63/138 80/151 \rightarrow 0.77 (0.55-1.07) $\geq -10\%$ 63/138 80/151 \rightarrow 0.77 (0.55-1.07) $1-49\%$ 44/127 62/115 \rightarrow 0.51 (0.34-0.75) $\geq 50\%$ 32/132 63/134 \rightarrow 0.51 (0.34-0.75) $\geq 50\%$ 32/132 63/134 \rightarrow 0.42 (0.28-0.65) EGFR mutation No 31/111 64/127 \rightarrow 0.48 (0.31-0.74) Yes 1/14 10/19 \rightarrow 0.09 (0.01-0.74) Unknown 107/272 131/254 \rightarrow 0.64 (0.49-0.83) ALK translocation No 29/104 76/133 \rightarrow 0.41 (0.26-0.62) Unknown 106/281 128/258 \rightarrow 0.63 (0.49-0.82) 0.01 0.10 0.20 0.50 1.00 3.00 Pembrolizumab Better Placebo Better	Squamous	66	/171	98/173				-	÷ !		0.57 (0.41-0.77)
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	PD-L1 TPS (50% cutoff)										, ,
≥50% 32/132 63/134 → 0.42 (0.28-0.65) PD-L1 TPS (1% cutoff) - 0.77 (0.55-1.07) 0.77 (0.55-1.07) ≥1% 76/259 125/249 → 0.47 (0.36-0.63) PD-L1 TPS - 0.77 (0.55-1.07) 0.77 (0.55-1.07) ≤1% 63/138 80/151 → 0.77 (0.55-1.07) 1-49% 44/127 62/115 → 0.51 (0.34-0.75) ≥50% 32/132 63/134 → 0.42 (0.28-0.65) EGFR mutation - 0.42 (0.28-0.65) 0.42 (0.28-0.65) Ves 1/14 10/19 → 0.48 (0.31-0.74) Ves 1/14 10/19 → 0.64 (0.49-0.83) ALK translocation - 0.64 (0.49-0.82) 0.61 (0.26-0.62) No 29/104 76/133 → 0.41 (0.26-0.62) 0.01 0.10 0.20 0.50 1.00 3.00 - 0.63 (0.49-0.82) 0.01 0.10 0.20 0.50 1.00 3.00 - Pembrolizumab Better Placebo Better	<50%	107	/265	142/266					-		0.64 (0.49-0.82)
PD-L1 TPS (1% cutoff) <1% 63/138 80/151 0.77 (0.55−1.07) 21% 63/138 80/151 0.47 (0.36−0.63) PD-L1 TPS <1%	≥50%	32	/132	63/134					-		0.42 (0.28-0.65)
<1% 63/138 80/151 0.77 (0.55−1.07) ≥1% 76/259 125/249 0.47 (0.36−0.63) PD-L1 TPS <1% 63/138 80/151 0.47 (0.36−0.63) 250% 32/132 63/134 0.51 0.51 (0.34−0.75) ≥50% 32/132 63/134 0.42 (0.28−0.65) EGFR mutation No 31/111 64/127 0.48 (0.31−0.74) Yes 1/14 10/19 0.48 (0.31−0.74) Yes 1/14 10/19 0.64 (0.49−0.83) ALK translocation No 29/104 76/133 0.41 (0.26−0.62) Unknown 106/281 128/258 0.61 0.03 0.05 1.00 3.00 Pembrolizumab Better Placebo Better	PD-L1 TPS (1% cutoff)								1		
≥1% 76/259 125/249 ● 0.47 (0.36-0.63) PD-L1 TPS 0.47 (0.36-0.63) 0.77 (0.55-1.07) 1-49% 44/127 62/115 ● 0.51 (0.34-0.75) ≥50% 32/132 65/134 ● 0.42 (0.28-0.65) EGFR mutation No 31/11 64/127 ● 0.48 (0.31-0.74) Yes 1/14 10/19 ● 0.09 (0.01-0.74) Unknown 107/272 131/254 ● 0.64 (0.49-0.83) ALK translocation 0.61 (0.28-0.62) 0.63 (0.49-0.82) 0.63 (0.49-0.82) Unknown 106/281 128/258 ● 0.61 (0.20 0.50 1.00 3.00 Pembrolizumab Better Placebo Better Placebo Better	<1%	63	/138	80/151					-		0.77 (0.55-1.07)
PD-L1 IPS 0.37138 80/151 → 0.77 (0.55-1.07) 1-49% 44/127 62/115 → 0.51 (0.34-0.75) ≥50% 32/132 63/134 → 0.42 (0.28-0.65) EGFR mutation 0.43 (0.31-0.74) 0.09 (0.01-0.74) No 31/111 64/127 → 0.48 (0.31-0.74) Unknown 107/272 131/254 → 0.64 (0.49-0.83) ALK translocation 0.64 (0.49-0.83) 0.64 (0.49-0.82) 0.63 (0.49-0.82) Unknown 106/281 128/258 → 0.60 (0.49-0.82) 0.01 0.10 0.20 0.50 1.00 3.00	≥1%	76	/259	125/249				-	-		0.47 (0.36-0.63)
< 170	PD-LI IPS	(A)	/120	20/153							0.77 (0.55 1.07)
1-1/2/0 14/12/ 02/113 03/10(34-0.73) 250% 32/132 63/134 0.42 (0.28-0.65) EGFR mutation 0.42 (0.28-0.65) 0.42 (0.28-0.65) Yes 1/14 10/19 0.09 (0.01-0.74) Unknown 107/272 131/254 0.64 (0.49-0.83) ALK translocation 0.61 (0.54-0.62) 0.63 (0.49-0.82) No 29/104 76/133 0.61 (0.10 0.20 0.50 1.00 3.00) Pembrolizumab Better Placebo Better	<170	03	/127	62/115							0.77 (0.55-1.07)
EGFR mutation 0.12 0.09 (0.10 0.09 (0.01 0.10 0.09 (0.01 0.10 0.09 (0.01 0.10 0.20 0.61 0.64 (0.49 - 0.83) 0.41 (0.26 - 0.62) 0.63 (0.49 - 0.82) 0.61 0.62 0.63 (0.49 - 0.82) 0.63 (0.49 - 0.82) 0.63 (0.49 - 0.82) 0.63 (0.49 - 0.82) 0.63 (0.49 - 0.82) 0.63 (0.49 - 0.82) 0.63 (0.49 - 0.82) 0.63 (0.49 - 0.82) 0.63 (0.41 - 0.20 - 0.50) 1.00 3.00 Periodizionab Placebo Better Placebo Better	>50%	32	/132	63/134				_			0.42 (0.28-0.65)
No 31/111 64/127 0.48 (0.31-0.74) Yes 1/14 10/19 0.09 (0.01-0.74) Unknown 107/272 131/254 0.64 (0.49-0.83) ALK translocation 0.41 (0.26-0.62) 0.63 (0.49-0.82) Unknown 106/281 128/258 0.01 0.10 0.20 0.50 1.00 3.00 Pembrolizumab Better Placebo Better	EGFR mutation	52	,	00/104					i		(0.20 0.00)
Yes 1/14 10/19 0.09 (0.01-0.74) Unknown 107/272 131/254 0.64 (0.49-0.83) ALK translocation 0.41 (0.26-0.62) 0.63 (0.49-0.82) No 29/104 76/133 0.61 (0.20 0.50 1.00 3.00) Unknown 106/281 128/258 0.01 0.10 0.20 0.50 1.00 3.00 Pembrolizumab Better Placebo Better	No	31	/111	64/127					←		0.48 (0.31-0.74)
Unknown 107/272 131/254 ALK translocation No 29/104 76/133 Unknown 106/281 128/258 0.01 0.10 0.20 0.50 1.00 3.00 Pembrolizumab Better Placebo Better	Yes	1	/14	10/19	<u>.</u>		+		_ !		0.09 (0.01-0.74)
ALK translocation No 29/104 76/133 0.41 (0.26-0.62) Unknown 106/281 128/258 0.01 0.10 0.20 0.50 1.00 3.00 Pembrolizumab Better Placebo Better	Unknown	107	/272	131/254					-		0.64 (0.49-0.83)
No 29/104 76/133 0.41 (0.26-0.62) Unknown 106/281 128/258 0.01 0.10 0.20 0.50 1.00 3.00 Pembrolizumab Better Placebo Better Placebo Better	ALK translocation								1		
Unknown 106/281 128/258 0.01 0.10 0.20 0.50 1.00 3.00 Pembrolizumab Better Placebo Better	No	29	/104	76/133					- :		0.41 (0.26-0.62)
0.01 0.10 0.20 0.50 1.00 3.00 Pembrolizumab Better Placebo Better	Unknown	106	/281	128/258	_				+ :		0.63 (0.49-0.82)
Pembrolizumab Better Placebo Better					0.01		0.10	0.20 0	.50 1.00	3.00	
Pembrolizumab Better Placebo Better					-						
						Pembr	olizumat	Better	P	acebo B	etter

Figure 1. Event-Free Survival as Assessed According to Investigator Review (Intention-to-Treat Population).

Panel A shows Kaplan–Meier estimates of event-free survival. Event-free survival was defined as the time from randomization to the first occurrence of local progression that precluded the planned surgery, unresectable tumor, progression or recurrence (according to the Response Evaluation Criteria in Solid Tumors, version 1.1) by the investigator's assessment, or death from any cause. The intention-to-treat population included all the participants who had undergone randomization. Tick marks indicate censored data. Panel B shows event-free survival in subgroups. The magnitude of the event-free survival treatment

effect in subgroups was calculated with the use of an unstratified Cox regression model with trial group as a covariate and Efron's method of handling ties. Race was reported by the participant. The subgroup of participants with ALK translocation (21 participants) was excluded from the forest plot because the statistical analysis plan specified that subgroups with less than 30 participants were to be excluded from the forest plot. PD-L1 denotes programmed death ligand 1, and TPS tumor proportion score.



Figure 2. Overall Survival (Intention-to-Treat Population). Tick marks indicate censored data.



Figure 3. Exploratory Analysis of Event-Free Survival According to Major Pathological Response and Pathological Complete Response (Intention-to-Treat Population).

Event-free survival was assessed according to investigator review. The hazard ratios for disease progression, disease recurrence, or death, along with the 95% confidence intervals, were calculated with the use of an unstratified Cox regression model with treatment as a covariate and Efron's method of handling ties. A major pathological response was defined as no more than 10% viable tumor cells in resected primary tumor and lymph nodes, and a pathological complete response as the absence of residual invasive cancer in resected

primary tumor and lymph nodes (ypT0/Tis ypN0) as assessed on the basis of blinded, central examination by a pathologist. Tick marks indicate censored data.

Table 1.

Baseline Demographics and Disease Characteristics (Intention-to-Treat Population)

	Pembrolizumab Group (N = 397)	Placebo Group (N = 400)		
Age				
Median (range) — yr	63 (26–83)	64 (35–81)		
65 yr — no. (%)	176 (44.3)	186 (46.5)		
Sex — no. (%)				
Female	118 (29.7)	116 (29.0)		
Male	279 (70.3)	284 (71.0)		
Race or ethnic group — no. (%)				
American Indian or Alaska Native	1 (0.3)	0		
Asian	124 (31.2)	125 (31.3)		
Black	6 (1.5)	10 (2.5)		
Multiple	3 (0.8)	10 (2.5)		
White	250 (63.0)	239 (59.8)		
Missing data	13 (3.3)	16 (4.0)		
Geographic region — no. (%)				
East Asia	123 (31.0)	121 (30.3)		
Other	274 (69.0)	279 (69.8)		
ECOG performance-status score *- no. (%)				
0	253 (63.7)	246 (61.5)		
1	144 (36.3)	154 (38.5)		
Smoking status — no. (%)				
Current smoker	96 (24.2)	103 (25.8)		
Former smoker	247 (62.2)	250 (62.5)		
Never smoked	54 (13.6)	47 (11.8)		
Pathological stage at baseline — no. (%)				
Ш	118 (29.7)	121 (30.3)		
Ш	279 (70.3)	279 (69.8)		
IIIA	217 (54.7)	225 (56.3)		
IIIB	62 (15.6)	54 (13.5)		
Tumor stage — no. (%)				
T1	55 (13.9)	61 (15.3)		
T2	106 (26.7)	126 (31.5)		
T3	121 (30.5)	109 (27.3)		
T4	115 (29.0)	104 (26.0)		
Node stage — no. (%)				
N0	148 (37.3)	142 (35.5)		
N1	81 (20.4)	71 (17.8)		

	Pembrolizumab Group (N = 397)	Placebo Group (N = 400)
N2	168 (42.3)	187 (46.8)
Histologic features — no. (%)		
Nonsquamous	226 (56.9)	227 (56.8)
Squamous	171 (43.1)	173 (43.3)
PD-L1 tumor proportion score — no. (%)		
50%	132 (33.2)	134 (33.5)
<50%	265 (66.8)	266 (66.5)
1-49%	127 (32.0)	115 (28.8)
<1%	138 (34.8)	151 (37.8)
EGFR mutation status — no. (%)		
No	111 (28.0)	127 (31.8)
Yes	14 (3.5)	19 (4.8)
Unknown	272 (68.5)	254 (63.5)
ALK translocation status — no. (%)		
No	104 (26.2)	133 (33.3)
Yes	12 (3.0)	9 (2.3)
Unknown	281 (70.8)	258 (64.5)

* The intention-to-treat population included all the participants who had undergone randomization. Percentages may not total 100 because of rounding. PD-L1 denotes programmed death ligand 1.

 $^+$ Race and ethnic group were reported by the participant

 $^{\pm}$ Eastern Cooperative Oncology Group (ECOG) performance-status scores range from 0 to 5, with 0 indicating no symptoms and higher scores indicating greater disability.

Table 2.

Treatment-Related Adverse Events Across Treatment Phases (As-Treated Population)

Event	Pembrolizumab Group (N = 396)	Placebo Group (N = 399)	
	number of participants (percent)		
Any treatment-related adverse event	383 (96.7)	379 (95.0)	
Grade 3-5 treatment-related adverse event	178 (44.9)	149 (37.3)	
Serious treatment-related adverse event	70 (17.7)	57 (14.3)	
Treatment-related adverse event that led to death	4 (1.0)*	3 (0.8)†	
Treatment-related adverse event that led to discontinuation of all trial treatment	50 (12.6)	21 (5.3)	

The as-treated population included all the participants who underwent randomization and received at least one dose of pembrolizumab or placebo plus chemotherapy. Treatment-related adverse events were adverse events considered by the investigator to be related to chemotherapy, pembrolizumab, or placebo.

⁺The causes of death were atrial fibrillation (in one participant), immune-mediated lung disease (in one), pneumonia (in one), and sudden cardiac death (in one); All deaths occurred during the neoadjuvant/surgery phase except for the death due to atrial fibrillation, which occurred during the adjuvant phase.

 $^{\pm}$ The causes of death were acute coronary syndrome (in one participant), pneumonia (in one), and pulmonary hemorrhage (in one); All deaths occurred during the neoadjuvant/surgery phase.

Table 3.

Treatment-Related Adverse Events with Incidence of 10% or Greater in Either Trial Group (As-Treated Population)

Event	Pembrolizumab	Group (N=396)	Placebo Group (N=399)		
	Any Grade	Grade 3–4	Any Grade	Grade 3–4	
Nausea	215 (54.3)	8 (2.0)	204 (51.1)	6 (1.5)	
Neutrophil count decreased	167 (42.2)	82 (20.7)	167 (41.9)	78 (19.5)	
Anemia	143 (36.1)	29 (7.3)	135 (33.8)	22 (5.5)	
White blood cell count decreased	111 (28.0)	21 (5.3)	98 (24.6)	22 (5.5)	
Fatigue	108 (27.3)	6 (1.5)	94 (23.6)	3 (0.8)	
Constipation	106 (26.8)	3 (0.8)	100 (25.1)	0	
Decreased appetite	91 (23.0)	6 (1.5)	88 (22.1)	0	
Vomiting	75 (18.9)	4 (1.0)	58 (14.5)	1 (0.3)	
Platelet count decreased	74 (18.7)	20 (5.1)	74 (18.5)	24 (6.0)	
Blood creatinine increased	56 (14.1)	3 (0.8)	48 (12.0)	0	
Diarrhea	52 (13.1)	6 (1.5)	56 (14.0)	3 (0.8)	
Alanine aminotransferase increased	51 (12.9)	7 (1.8)	31 (7.8)	4 (1.0)	
Asthenia	45 (11.4)	4 (1.0)	55 (13.8)	2 (0.5)	
Rash	45 (11.4)	3 (0.8)	26 (6.5)	0	
Alopecia	40 (10.1)	0	40 (10.0)	1 (0.3)	

Author Manuscript